52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 66

Background

The standard treatment for early breast cancer with node-negative axilla is wide local excision (WLE) and sentinel lymph node biopsy (SNB). Guide-wire WLE for impalpable cancers poses various challenges. The use of magnetic seeds has been adopted as an alternative solution. Difficult detectability, magnetic interference with metallic instruments/MRI, and recalibration remain open issues. The common technique for SNB is radioisotope with or without blue dye. The radioisotope poses various problems including handling and disposal of isotopes. The short half-life of the isotope restricts the scheduling of surgery and hinders patients’ flow into the operating theater. Finally, concerns have previously been raised regarding the efficacy of ICG in patients with high body mass index (BMI). We present our experience in WLE plus SNB using a non-wire, non-magnetic breast localization method plus non-radioisotope technique for sentinel node identification. A comparison with the magnetic breast localization method is provided. The aims of the study are:

  1. Compare oncological clearance of cancer between magnetic and nonmagnetic localization seeds.
  2. Demonstrate a good identification rate of SNB using a
    non-radioisotope fluorescent dye.
  3. Confirm good node detection rate with the ICG regardless of patients’ BMI.

Methods

Patient and Tumor Characteristics of Patients Having WLE With SAVI SCOUT and Magseed

Patient and Tumor Characteristics of Patients Having WLE With SAVI SCOUT and Magseed

We compared 50 patients with WLE and SNB using SAVI SCOUT plus ICG with 50 cases using Magseed plus ICG in 2022/2023. The SAVI SCOUT clip was placed 1 to 5 days before surgery. Additionally, 2 mL of ICG and 2 mL of blue dye were injected intradermally in the periareolar area.

Results

The identification rate of SNB with ICG dye was 100% despite high BMI. Also, BMI has not affected the number of nodes retrieved (average number of SNB was 2, similar to other case series). A total of 5 of the patients localized with SAVI SCOUT had positive margins (10%) compared with 6 localized with magnetic seed (12%). The re-excision rate using SAVI SCOUT/Magseed is not statistically significant. Compared with guide wire, the use of SAVI SCOUT reduced the re-excision rate by 50% in our case series (15% vs 10%).

Conclusions

Non-magnetic localization of impalpable breast cancers showed a good detection rate with adequate margins clearance (10% re-excision rate, compared with 17.2% UK average). The use of ICG in SNB (with blue dye) is associated with an identification rate of 100% regardless of high BMI. Preoperative admission and preparation for surgery are streamlined by avoiding the need for wire localization and radioisotope injection.

Articles in this issue

41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
48 The Era ‘or Error’ of Second Localization Procedures
48 The Era ‘or Error’ of Second Localization Procedures
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table